Circulation Research · 2018 · 175 citations · 33 references
Veterinary MedicinePathobiologyPathologyCellular PathologyImmunopathologyInflammationExtracellular MatrixInflammatory MediatorsInflammatory PathologyInflammatory Tissue InjuryMacrophage BiologyVascular PathologyArterial Wall ThickeningMatrix MetalloproteinasesMedium-vessel VasculitisMonocyte-derived MacrophagesType Iv CollagenVascular RemodelingVasculitic InflammationVasculitis Pathogenesis
Rationale: Giant cell arteritis (GCA)—a primary vasculitis of medium and large arteries—is associated with vessel wall damage, elastic membrane fragmentation, and vascular remodeling. Proteinases are believed to contribute to pathogenesis by degrading extracellular matrix and causing tissue injury. Objective: The MMP (matrix metalloproteinase)-9—a type IV collagenase—is produced in the vasculitic lesions of GCA. It is unknown which pathogenic processes are MMP-9 dependent. Methods and Results: The tissue transcriptome of GCA-affected temporal arteries contained high amounts of MMP-9 transcripts, and immunostaining for pro-MMP-9 localized the enzyme to wall-infiltrating macrophages. MMP-2 and MMP-9 transcripts were also abundant in monocytes and monocyte-derived macrophages from patients with GCA. Patient-derived monocytes outperformed healthy monocytes in passing through engineered basement membranes. GCA CD (cluster of differentiation) 4 + T cells required MMP-9–producing monocytes to penetrate through matrix built from type IV collagen. In vivo functions of MMP-9 were tested in a human artery-SCID (severe combined immunodeficiency) chimera model by blocking enzyme activity with a highly specific monoclonal antibody or by injecting rMMP-9 (recombinant MMP-9). Inhibiting MMP-9 activity profoundly suppressed vascular injury, decreased the density of inflammatory infiltrates ( P <0.001), reduced intramural neoangiogenesis ( P <0.001), and prevented intimal layer hyperplasia ( P <0.001). rMMP-9 amplified all domains of vasculitic activity, promoted assembly of T-cell infiltrates ( P <0.05), intensified formation of new microvessels ( P <0.001), and worsened intimal thickening ( P <0.001). Systemic delivery of N-acetyl-proline-glycine-proline—a matrikine produced by MMP-9–mediated gelatinolysis—had limited vasculitogenic effects. Conclusions: In large vessel vasculitis, MMP-9 controls the access of monocytes and T cells to the vascular wall. T cells depend on MMP-9–producing monocytes to pass through collagen IV-containing basement membrane. Invasion of vasculitogenic T cells and monocytes, formation of neoangiogenic networks, and neointimal growth all require the enzymatic activity of MMP-9, identifying this protease as a potential therapeutic target to restore the immunoprivilege of the arterial wall in large vessel vasculitis.
33
Zorina S. Galis, Galina K. Sukhova, Michael W. Lark et al. · Journal of Clinical Investigation · 1994 · 2.5K citations · Full text
Trial of Tocilizumab in Giant-Cell Arteritis
John H. Stone, Katie Tuckwell, Sophie Dimonaco et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text
Th17 and Th1 T-Cell Responses in Giant Cell Arteritis
Jiusheng Deng, Brian R. Younge, Richard A. Olshen et al. · Circulation · 2010 · 427 citations · Full text